Cytochrome P450 3A5 plays a prominent role in the oxidative metabolism of the anti-human immunodeficiency virus drug maraviroc

Drug Metabolism and Disposition

Volumn 40, Issue 12, 2012, Pages 2221-2230

  Lu, Yanhui ^a   Hendrix, Craig W ^a   Bumpus, Namandjé N ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOHEXANE DERIVATIVE; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; DICHLOROCYCLOHEXANE; MARAVIROC; UNCLASSIFIED DRUG;

ALLELE; ARTICLE; CONTROLLED STUDY; DRUG GLUCURONIDATION; DRUG HYDROXYLATION; DRUG METABOLISM; DRUG OXIDATION; DRUG TRANSFORMATION; ENZYME ACTIVITY; HOMOZYGOTE; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; IN VITRO STUDY; IN VIVO STUDY; LIVER MICROSOME; LOSS OF FUNCTION MUTATION; MALE; MASS SPECTROMETRY; METABOLITE; NORMAL HUMAN; OXYGENATION; PRIORITY JOURNAL; PROTEIN FUNCTION; SINGLE DRUG DOSE; ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY; WILD TYPE;

ALLELES; AMINO ACID SEQUENCE; ANIMALS; CERCOPITHECUS AETHIOPS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; COS CELLS; CYCLOHEXANES; CYTOCHROME P-450 CYP3A; HIV FUSION INHIBITORS; HUMANS; HYDROXYLATION; MALE; MASS SPECTROMETRY; METABOLIC DETOXICATION, PHASE I; MICROSOMES, LIVER; MOLECULAR SEQUENCE DATA; MUTATION; TRIAZOLES;

HUMAN IMMUNODEFICIENCY VIRUS;

EID: 84869119409     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.112.048298     Document Type: Article

References (43)

1. Abel S, Russell D, Whitlock LA, Ridgway CE, Nedderman AN, and Walker DK (2008a) Assessment of the absorption, metabolism and absolute bioavailability of maraviroc in healthy male subjects. Br J Clin Pharmacol 65 (Suppl):60-67.
2. Abel S, van der Ryst E, Rosario MC, Ridgway CE, Medhurst CG, Taylor-Worth RJ, and Muirhead GJ (2008b) Assessment of the pharmacokinetics, safety and tolerability of maraviroc, a novel CCR5 antagonist, in healthy volunteers. Br J Clin Pharmacol 65 (Suppl):5-18.
3. Bennett WM and Norman DJ (1986) Action and toxicity of cyclosporine. Annu Rev Med 37:215-224.
4. Boffito M and Abel S (2008) A review of the clinical pharmacology of maraviroc. Introduction. Br J Clin Pharmacol 65 (Suppl):1-4.
5. Daly AK (2006) Significance of the minor cytochrome P450 3A isoforms. Clin Pharmacokinet 45:13-31.
6. Dennison JB, Jones DR, Renbarger JL, and Hall SD (2007) Effect of CYP3A5 expression on vincristine metabolism with human liver microsomes. J Pharmacol Exp Ther 321:553-563.
7. Dennison JB, Kulanthaivel P, Barbuch RJ, Renbarger JL, Ehlhardt WJ, and Hall SD (2006) Selective metabolism of vincristine in vitro by CYP3A5. Drug Metab Dispos 34:1317-1327.
8. Dennison JB, Mohutsky MA, Barbuch RJ, Wrighton SA, and Hall SD (2008) Apparent high CYP3A5 expression is required for significant metabolism of vincristine by human cryopreserved hepatocytes. J Pharmacol Exp Ther 327:248-257.
9. Domanski TL, Liu J, Harlow GR, and Halpert JR (1998) Analysis of four residues within substrate recognition site 4 of human cytochrome P450 3A4: role in steroid hydroxylase activity and α-naphthoflavone stimulation. Arch Biochem Biophys 350:223-232.
10. Dorr P, Westby M, Dobbs S, Griffin P, Irvine B, Macartney M, Mori J, Rickett G, Smith-Burchnell C, Napier C, et al. (2005) Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity. Antimicrob Agents Chemother 49:4721-4732.
11. Egbelakin A, Ferguson MJ, MacGill EA, Lehmann AS, Topletz AR, Quinney SK, Li L, McCammack KC, Hall SD, and Renbarger JL (2011) Increased risk of vincristine neurotoxicity associated with low CYP3A5 expression genotype in children with acute lymphoblastic leukemia. Pediatr Blood Cancer 56:361-367.
12. Emoto C and Iwasaki K (2006) Enzymatic characteristics of CYP3A5 and CYP3A4: a comparison of in vitro kinetic and drug-drug interaction patterns. Xenobiotica 36:219-233.
13. Fätkenheuer G, Pozniak AL, Johnson MA, Plettenberg A, Staszewski S, Hoepelman AI, Saag MS, Goebel FD, Rockstroh JK, Dezube BJ, et al. (2005) Efficacy of short-term monotherapy with maraviroc, a new CCR5 antagonist, in patients infected with HIV-1. Nat Med 11:1170-1172.
14. Guilhaumou R, Solas C, Bourgarel-Rey V, Quaranta S, Rome A, Simon N, Lacarelle B, and Andre N (2011) Impact of plasma and intracellular exposure and CYP3A4, CYP3A5, and ABCB1 genetic polymorphisms on vincristine-induced neurotoxicity. Cancer Chemother Pharmacol 68:1633-1638.
15. Guo Y, Zhang Y, Wang Y, Chen X, Si D, Zhong D, Fawcett JP, and Zhou H (2005) Role of CYP2C9 and its variants (CYP2C9*3 and CYP2C9*13) in the metabolism of lornoxicam in humans. Drug Metab Dispos 33:749-753.
16. Hardy WD, Gulick RM, Mayer H, Fätkenheuer G, Nelson M, Heera J, Rajicic N, and Goodrich J (2010) Two-year safety and virologic efficacy of maraviroc in treatment-experienced patients with CCR5-tropic HIV-1 infection: 96-week combined analysis of MOTIVATE 1 and 2. J Acquir Immune Defic Syndr 55:558-564.
17. Harlow GR and Halpert JR (1997) Alanine-scanning mutagenesis of a putative substrate recognition site in human cytochrome P450 3A4. Role of residues 210 and 211 in flavonoid activation and substrate specificity. J Biol Chem 272:5396-5402.
18. He YA, He YQ, Szklarz GD, and Halpert JR (1997) Identification of three key residues in substrate recognition site 5 of human cytochrome P450 3A4 by cassette and site-directed mutagenesis. Biochemistry 36:8831-8839.
19. Hooper DK, Fukuda T, Gardiner R, Logan B, Roy-Chaudhury A, Kirby CL, Vinks AA, and Goebel J (2012) Risk of tacrolimus toxicity in CYP3A5 nonexpressors treated with intravenous nicardipine after kidney transplantation. Transplantation 93:806-812.
20. Hustert E, Haberl M, Burk O, Wolbold R, He YQ, Klein K, Nuessler AC, Neuhaus P, Klattig J, Eiselt R, et al. (2001) The genetic determinants of the CYP3A5 polymorphism. Pharmacogenetics 11:773-779.
21. Hyland R, Dickins M, Collins C, Jones H, and Jones B (2008) Maraviroc: in vitro assessment of drug-drug interaction potential. Br J Clin Pharmacol 66:498-507.
22. Kamdem LK, Streit F, Zanger UM, Brockmöller J, Oellerich M, Armstrong VW, and Wojnowski L (2005) Contribution of CYP3A5 to the in vitro hepatic clearance of tacrolimus. Clin Chem 51:1374-1381.
23. Khan KK and Halpert JR (2000) Structure-function analysis of human cytochrome P450 3A4 using 7-alkoxycoumarins as active-site probes. Arch Biochem Biophys 373:335-345.
24. Khan KK, He YQ, Domanski TL, and Halpert JR (2002) Midazolam oxidation by cytochrome P450 3A4 and active-site mutants: an evaluation of multiple binding sites and of the metabolic pathway that leads to enzyme inactivation. Mol Pharmacol 61:495-506.
25. Kuehl P, Zhang J, Lin Y, Lamba J, Assem M, Schuetz J, Watkins PB, Daly A, Wrighton SA, Hall SD, et al. (2001) Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet 27:383-391.
26. Levitt LP and Prager D (1975) Mononeuropathy due to vincristine toxicity. Neurology 25:894-895.
27. Mannu J, Jenardhanan P, and Mathur PP (2011) A computational study of CYP3A4 mediated drug interaction profiles for anti-HIV drugs. J Mol Model 17:1847-1854.
28. Min DI, Ellingrod VL, Marsh S, and McLeod H (2004) CYP3A5 polymorphism and the ethnic differences in cyclosporine pharmacokinetics in healthy subjects. Ther Drug Monit 26:524-528.
29. Naesens M, Kuypers DR, and Sarwal M (2009) Calcineurin inhibitor nephrotoxicity. Clin J Am Soc Nephrol 4:481-508.
30. Pearson JT, Wahlstrom JL, Dickmann LJ, Kumar S, Halpert JR, Wienkers LC, Foti RS, and Rock DA (2007) Differential time-dependent inactivation of P450 3A4 and P450 3A5 by raloxifene: a key role for C239 in quenching reactive intermediates. Chem Res Toxicol 20:1778-1786.
31. Renders L, Frisman M, Ufer M, Mosyagin I, Haenisch S, Ott U, Caliebe A, Dechant M, Braun F, Kunzendorf U, et al. (2007) CYP3A5 genotype markedly influences the pharmacokinetics of tacrolimus and sirolimus in kidney transplant recipients. Clin Pharmacol Ther 81:228-234.
32. Rendic S and Di Carlo FJ (1997) Human cytochrome P450 enzymes: a status report summarizing their reactions, substrates, inducers, and inhibitors. Drug Metab Rev 29:413-580.
33. Roussel F, Khan KK, and Halpert JR (2000) The importance of SRS-1 residues in catalytic specificity of human cytochrome P450 3A4. Arch Biochem Biophys 374:269-278.
34. Sevrioukova IF and Poulos TL (2010) Structure and mechanism of the complex between cytochrome P4503A4 and ritonavir. Proc Natl Acad Sci USA 107:18422-18427.
35. Shevchenko VP, Nagaev IY, and Myasoedov NF (2009) Introduction of hydrogen isotopes into maraviroc and mass-spectrometric study of deuterium distribution. Radiochemistry 51:175-177.
36. Takashina Y, Naito T, Mino Y, Yagi T, Ohnishi K and Kawakami J (2012) Impact of CYP3A5 and ABCB1 gene polymorphisms on fentanyl pharmacokinetics and clinical responses in cancer patients undergoing conversion to a transdermal system. Drug Metab Pharmacokinet http://dx.doi.org/10.2133/dmpk.DMPK-11-RG-134.
37. van Schaik RH, van der Heiden IP, van den Anker JN, and Lindemans J (2002) CYP3A5 variant allele frequencies in Dutch Caucasians. Clin Chem 48:1668-1671.
38. Walker DK, Abel S, Comby P, Muirhead GJ, Nedderman AN, and Smith DA (2005) Species differences in the disposition of the CCR5 antagonist, UK-427,857, a new potential treatment for HIV. Drug Metab Dispos 33:587-595.
39. Wang H, Dick R, Yin H, Licad-Coles E, Kroetz DL, Szklarz G, Harlow G, Halpert JR, and Correia MA (1998) Structure-function relationships of human liver cytochromes P450 3A: aflatoxin B1 metabolism as a probe. Biochemistry 37:12536-12545.
40. Williams PA, Cosme J, Vinkovic DM, Ward A, Angove HC, Day PJ, Vonrhein C, Tickle IJ, and Jhoti H (2004) Crystal structures of human cytochrome P450 3A4 bound to metyrapone and progesterone. Science 305:683-686.
41. Wright P, Alex A, Nyaruwata T, Parsons T, and Pullen F (2010) Using density functional theory to rationalise the mass spectral fragmentation of maraviroc and its metabolites. Rapid Commun Mass Spectrom 24:1025-1031.
42. Yano JK, Wester MR, Schoch GA, Griffin KJ, Stout CD, and Johnson EF (2004) The structure of human microsomal cytochrome P450 3A4 determined by X-ray crystallography to 2.05-A resolution. J Biol Chem 279:38091-38094.
43. Zawaira A, Ching LY, Coulson L, Blackburn J, and Wei YC (2011) An expanded, unified substrate recognition site map for mammalian cytochrome P450s: analysis of molecular interactions between 15 mammalian CYP450 isoforms and 868 substrates. Curr Drug Metab 12:684-700.